Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,258,724 papers from all fields of science
Search
Sign In
Create Free Account
E 7010
Known as:
E-7010
, E7010
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
ABT751
Broader (2)
Aminophenols
Sulfonamides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Design, synthesis and evaluation of novel sulfonamides as potential anticancer agents
M. Kachaeva
,
D. Hodyna
,
+5 authors
V. Brovarets
Comput. Biol. Chem.
2018
Corpus ID: 19073663
2008
2008
Inhibitors of Tubulin Assembly Identified through Screening a Compound Library
R. E. Morgan
,
Sunjoo Ahn
,
+7 authors
K. Werbovetz
Chemical Biology and Drug Design
2008
Corpus ID: 205912799
Tubulin is the proposed target for drugs against cancer and helminths and is also a validated target in kinetoplastid parasites…
Expand
Highly Cited
2002
Highly Cited
2002
Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis.
A. Yokoi
,
J. Kuromitsu
,
+5 authors
T. Owa
Molecular Cancer Therapeutics
2002
Corpus ID: 11855385
A series of small molecules from sulfonamide-focused libraries have been evaluated in these laboratories to discover novel…
Expand
Highly Cited
2002
Highly Cited
2002
Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4…
T. Owa
,
A. Yokoi
,
K. Yamazaki
,
K. Yoshimatsu
,
T. Yamori
,
T. Nagasu
Journal of Medicinal Chemistry
2002
Corpus ID: 23584256
Compounds from sulfonamide-focused libraries have been evaluated in cell-based antitumor screens using the COMPARE analysis with…
Expand
2001
2001
Novel sulfonate derivatives: potent antimitotic agents.
S. L. Gwaltney
,
H. Imade
,
+8 authors
H. Sham
Bioorganic & Medicinal Chemistry Letters
2001
Corpus ID: 9532034
2000
2000
Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor
Y. Funahashi
,
N. Koyanagi
,
K. Kitoh
Cancer Chemotherapy and Pharmacology
2000
Corpus ID: 19773622
Abstract. Purpose: E7010 is an orally active sulfonamide antitumor agent showing good activity against various subcutaneously…
Expand
Highly Cited
1999
Highly Cited
1999
Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy
Y. Nihei
,
Manabu Suzuki
,
+6 authors
Yasufumi Sato
Japanese journal of cancer research : Gann
1999
Corpus ID: 13724831
Tubulin binding agents (TBAs) reduce tumor perfusion and inhibit mitosis of tumor cells in solid tumors, but it is not clear…
Expand
Highly Cited
1998
Highly Cited
1998
Phase I study of E7010
Kaichiro Yamamoto
,
K. Noda
,
A. Yoshimura
,
M. Fukuoka
,
K. Furuse
,
H. Niitani
Cancer Chemotherapy and Pharmacology
1998
Corpus ID: 27924921
Abstract E7010 is a novel sulfonamide which was discovered using slow-growing colon 38 carcinoma cells as a screening model…
Expand
1998
1998
Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines
Y. Iwamoto
,
K. Nishio
,
H. Fukumoto
,
K. Yoshimatsu
,
M. Yamakido
,
N. Saijo
Japanese journal of cancer research : Gann
1998
Corpus ID: 13718311
N‐[2‐[(4‐Hydroxyphenyl)amino]‐3‐pyridyl]‐4‐methoxybenzenesulfonamide (E7010) is a novel sulfonamide antimitotic agent, which is…
Expand
Highly Cited
1997
Highly Cited
1997
Antitumor Activity of TZT‐1027, a Novel Doiastatin 10 Derivative
M. Kobayashi
,
T. Natsume
,
+8 authors
S. Tsukagoshi
Japanese journal of cancer research : Gann
1997
Corpus ID: 13717828
Dolastatin 10, a pentapeptide isolated from the marine mollusk Dolabella auricularia, has antitumor activity. TZT‐1027, a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE